Conversion of approximately 90% of outstanding Series C Preferred Stock represents a significant milestone in the Company’s plan to strengthen its balance sheet and regain compliance with Nasdaq listing standards. CHARLOTTE, N.C., June 08, 2026 (GLOBE NEWSWIRE) — Alpha Modus Holdings, Inc. (“Alpha Modus”) (NASDAQ: AMOD) (“Alpha Modus” or the “Company”), a leader in AI-driven retail technology and financial services infrastructure, today announced the completion of the previously disclosed conversion of approximately 3.87 million shares of Series C Preferred Stock held by one of the Alessi family trusts into shares of the Company’s common stock. The transaction, first announced by the Company in April 2026, represents the conversion of approximately 90% of the Company’s outstanding Series C Preferred Stock and...

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577Date Total number of shares representing the share capital Total number of voting rightsMay, 31 2026 8 390 660 Gross total of voting rights : 12 706 758Net total* of voting rights : 12 697 722Net total* = total number of voting rights attached to the total number of shares net of shares with no voting rights. VIRBAC: Shaping the future of animal healthNYSE Euronext – Compartiment A / Code ISIN: FR0000031577 / MNEMO: VIRPCorporate Finance: tel. 33 4 92 08 71 32 / Email: finances@virbac.comWebsite:...

BEIJING, China, June 08, 2026 (GLOBE NEWSWIRE) — Zhihu Inc. (NYSE: ZH; HKEX: 2390) (“Zhihu” or the “Company”), a leading online content community in China, today announced that it will hold an annual general meeting of the Company’s shareholders (the “AGM”) at 10:00 a.m. Beijing time on June 30, 2026 at Room Xinzhi, Floor 1, Zone C, China Industry-Academy-Research Achievement Transformation Center, No. 18A Xueqing Road, Haidian District, Beijing, China, for the purposes of considering and, if thought fit, passing each of the Proposed Resolutions as defined and set forth in the notice of the AGM (the “AGM Notice”). The AGM Notice and the form of proxy for the AGM are available on the Company’s website at https://ir.zhihu.com. The board of directors of the Company fully supports the Proposed Resolutions and recommends that shareholders...

SHENZHEN, CHINA, June 08, 2026 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”), have been presented in a poster at the American Diabetes Association (ADA) 86th Scientific Sessions (June 5-8, 2026, New Orleans, USA). As the world’s largest and most authoritative annual scientific meeting in the fields of diabetes and metabolic diseases, it convened over 12,000 leading clinicians, researchers, and healthcare professionals worldwide to explore cutting-edge advances in diagnostics, therapies, and technologies. About CMS-D008CMS-D008 is a self-developed novel siRNA therapy administered by subcutaneous injection....

Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of clinical benefit  Vopimetostat combinations with Revolution Medicines’ RAS(ON) inhibitors daraxonrasib or zoldonrasib were generally well-tolerated Data support rapid advancement of vopimetostat plus daraxonrasib combination into Phase 3 development in first-line MTAP deleted pancreatic cancer Conference call today, June 8, 2026, at 8:00am ET BOSTON, June 08, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced positive initial data from its ongoing Phase 1/2 study...

HOUSTON, June 08, 2026 (GLOBE NEWSWIRE) — Devon Energy Corporation (NYSE: DVN) (“Devon”) today announced that, in connection with the previously announced offers to Eligible Holders (as defined herein) to exchange (each, an “Exchange Offer” and collectively, the “Exchange Offers”) any and all outstanding notes issued by Coterra Energy Inc., a direct, wholly owned subsidiary of Devon (“Coterra”), as set forth in the table below (the “Existing Coterra Notes”) for (1) new notes issued by Devon (the “New Devon Notes”) and (2) cash, and solicitations of consents by Coterra from Eligible Holders (each, a “Consent Solicitation” and, collectively, the “Consent Solicitations”) to adopt certain proposed amendments to each of the corresponding indentures governing the Existing Coterra Notes (other than the Existing Coterra OpCo Notes (as...